Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Wound Management Technologies — Investor Presentation (October 2010)
31 slides from Sanara Medtech's investor presentation, Oct 6, 2010
Slide 1: Wound Management Technologies
| Wound Management 2 cy TECHNOLOGIES, INC. Arapidly growing provider of specialty medical products, advanced biotechnology solutions and technology applications.
Slide 2: Safe Harbor Statement
Safe Harbor Statement ‘Statements in this Presentation are made as of the date of this Presentation unless stated otherwise and are subject to change, completion, or amendment without notice. Neither the delivery of this Presentation at any time shall under any circumstances create an implication th
Slide 3: Wound Management Technologies: Biotech and eHealth
Wound Management CSD) TECHNOLOGIES, INC. BIOTECH eHEALTH Secure Health... OP trrrcrese res.
Slide 4: Wound Management Markets
Wound Management Markets Wound Management’s unique patented CellerateRX® products address the very large and growing advanced wound care markets. » U.S. market in 2007 was $3.0B and is projected to double by 2013 Total U.S. Advanced Wound Care Market $Millions 2008 20135 alants and anti-adhesion pro
Slide 5: Wound Care
Wound Care Innovations, LLC M@Szge4ex The CellerateRX® advantage is in the patented, Activated Collagen™ fragments (CRXa™) combined with the properties of the Type |, bovine-sourced, material. CellerateRX ® provides the wound site with a form of collagen that is unique as it is ready to be used imme
Slide 6: Why CellerateRX?
Why CellerateRX®? > CellerateRX® is available in powder and gel forms > It is a unique, patented, activated collagen that delivers immediate benefits to the wound > Cost-effective > Both in product cost and in labor involved > Biocompatible and biodegradable > Unprecedented range of use in every wou
Slide 7: Reimbursed by Medicare Part B
Reimbursed by Medicare Part B Regulated as a medical device > CellerateRX® does not require a prescription FDA cleared for all wounds* including: +Except 3° degree burns Certifications in process: > ISO 9001:2008/13485:2003/CMDCAS and MDD(CE) > Anticipate CE mark in 1Q 2011 fidental of Wound Te Ine.
Slide 8: Wound Care Statistics
Wound Care Statistics + Each year between 5M and 7M chronic and/or complex wounds occur in the U.S. The annual cost for overall management of these wounds is > $20B annually, not including the additional costs to society in terms of lost workdays or productivity. * Chronic leg wounds (ulcers) alone
Slide 9: Market Segment Penetration
Market Segment Penetration a. section added + Long Term Care Facilities conmracted { 4 pee rey \ * Hospitals (including VHA) Distroutors sll to A EV Wound Care Centers “ . *. u \ 1 7. Sales model \ g * Home Health Agencies oe depen © ° Physicians, Surgeons pees y, —— facilities and |”) + Podiatrists
Slide 10: Diabetes — A Worldwide Epidemic, a Prime Market
Diabetes — A Worldwide Epidemic, a Prime Market for CellerateRX® ‘According to the IDF, approximately 285M people will live with \ i§ diabetes in 2010. WHO projects this to grow to 360M by 2030 Diabetes affects approximately 24M Americans; 57M are pre- § diabetic and likely to develop diabetes withi
Slide 11: CellerateRX in Surgical Settings
CellerateRX® in Surgical Settings > Can be used on any post-operative procedure > Can be used on non-closure / dehiscenced wounds > Minimizes potential for scarring > Collagen has been shown to reduce wound pain > Gel provides protective barrier
Slide 12: CellerateRX International Sales
CellerateRX® International Sales > Middle East (2009) > Lebanon (1Q 2010) » Pending Sales: Saudi Arabia, Iran, Dubai, Qatar > Europe (Italy: 2009, pending registration) > South Africa (3Q 2010; other African nations in process) > Central America (5 Countries, 3Q 2010) > Registration in process: Colu
Slide 13: Sales Team in Place
Sales Team in Place > Poised for Growth: having completed evidence- based studies , Wound Management developed its sales channel plan and engaged sales and marketing executives in April 2010. > Growth from: — Growing brand recognition — New direct reps in Florida, National Account Manager Channel pa
Slide 14: CellerateRX Sales by Year
CellerateRX® $2,000 Est — Year End $1,000 - $631 ——5$610 Orders -3Q $500 —$190 $290 s: Thousands £ a t=} o | 2006 2007 2008 2009 2010 — Estimated —Actual Sales Activities (tracked in CMS) 280 Active Accounts 940 Prospects Active fidental of Wound Te Ine. 14
Slide 15: CellerateRX Orders
CellerateRX® Orders » © $1,600 ees) 2/2 Est. Hy TA g ° 2 é $1,200, ———_____— — — $200 ——— 1Q 2010 2Q 2010 3Q2010Est. 4Q 2010 Est — Quarterly fidential of Wound Te Ine. 15
Slide 16: Estimated USA Total Order Volume YTD
110 Estimated USA Total Order Volume YTD ‘% of States In States Category ‘Order Volume No Orders $500 22.6056 32.10% $5,000, $50,000 13.20% to $500,000 3.80% of Wound
Slide 17: Sales Activities — 2010 Domestic
Sales Activities — 2010 Domestic * Over 1,000 new providers contacted * 71 new product evaluations done in Q2 and Q3 — 6 “unsuccessful” * 1 (wrong secondary dressing used) * 3 (powder, not gel, should have been used) * 1 (nurse didn’t “like”) * 1 (unspecified) ¢ Major distribution contracts — Southe
Slide 18: Biotech Pipeline
Biotech Pipeline YP RESORBABLE G ~ ORTHOPEDIC PRODUCTS, LLC Resorbable Bone Wax & Bone Void Filler products > $1.4B Worldwide Bio Materials Market » Resorbable orthopedic hemostat used to stop blood flow & delivery system for osteogenic / osteoinductive orthopedic products > Less than $100k to final
Slide 19: Resorbable Bone Wax
Resorbable Bone Wax Features: Benefits: > Hemostasis efficacy is > Efficacy immediate > Low Cost (price > Performance & competitive to handling beeswax) characteristics are > Reduced potential for identical to the infection ae bone ae > Elimination of potential surgeons have used in fornonevax the p
Slide 20: Comparison to Other Hemostatic Agents
Comparison to Other Hemostatic Agents Design: Resorbtion: > Current concept > 8- 12 hours envisions a similar > Applications: design to conventional bone wax. Input carn welcome > Cardiovascular > Performance: » Orthopedic | A 5 Plastic and > Equivalent hemostasis 1” . g Reconstructive Dental to Eth
Slide 21: Product Extensions
Product Extensions > In addition to Resorbable Bone Wax, the patent covers a resorbable hemostatic dressing with antimicrobials and antibacterials > This opens the door to a dressing which will control bleeding as well as microbial growth within the dressing > The patent also covers bone void filler
Slide 22: Secure eHealth
Secure eHealth. Provider of secure communications solutions across all segments of the healthcare industry. > Single most critical component necessary for any healthcare community is secure communication > Target Markets * Health Information Exchanges + Disease Management Organizations * Clinical Tr
Slide 23: Secure eHealth Product Suite
~ Secure eHealth.. Acomplete suite of scalable products for secure, intelligent healthcare communication, collaboration, storage and transport >» HIPAA/ARRA compliant > Cross platform compatible, including handheld devices for complete mobility > Simple integration with present systems fidentat of W
Slide 24: Secure eHealth: Timing and Advantages
Secure eHealth.. > Timing is Perfect: > Pressure continues to mount for more collaborative healthcare delivery which mandate “secure” communication > Billions available in HIT stimulus initiatives require security in order to qualify for meaningful use > Distinct Advantages + Existing partnerships *
Slide 25: Key Strategic Partnerships
Secure eHealth.. Key Strategic Partnerships » HealthPoints Inc. — Diabetic Disease Management Project > GSI Health, Inc. - Collaborative security infrastructure for HIE, HIN, RHIO projects » Private Access, Inc. — Licensee of Envoii secure notification tools for patient privacy platform Emerging Opp
Slide 26: Management
Management > Scott Haire, Chairman/CEO, has over 16 years experience in the wound care products industry and in eHealth management systems. > Deborah Jenkins Hutchinson, President, has over 30 years of experience in both healthcare and technology sectors with a successful track record of taking earl
Slide 27: Management, continued
Management, continued > Robert Tapales, President of Secure eHealth, LLC Division. Robert has over 20 years in health management experience having previously served as EVP and COO for several healthcare technology companies, and most recently as EVP for VirtualHealth Technologies, Inc. » Barry Const
Slide 28: Stock Overview
Stock Overview = Symbol: = Exchange: = Shares Outstanding: = Estimated Float: = Last Trade: = Market capitalization: Fiscal Year: Wound Management Technology, Inc. (WNDM) is a rapidly growing provider of advanced biotechnology products and eHealth technology solutions. WNDM OTC BB 35,341,938 (2Q 201
Slide 29: WNDM News Highlights
WNDM News Highlights * 10/5/10 — All-Time High in Q Orders ; Q3 Includes First Pharmacy Group Order for Cellerate RX® + 9/29/10 — Government Marketing & Procurement relationship + 9/16/10 — Panama Distributor + 9/9/10 -WNDM adds VHA Facilities (9 current) + 8/26/10 — Central Medical Systems added as
Slide 30: Mithra Research
MITHRA RESEARCH “Taming the Divine Bull” Independent Research published July 28, 2010 We are of the opinion that CellerateRX® ought to be standard issue in every hospital, emergency rooms, every soldier's field kit; it should be in the medical supplies of schools and Universities; every student's ba
Slide 31: Wound Management Technologies Contact
An; Ay Wound Management TECHNOLOGIES, INC. 777 Main Street, Suite 3100 Fort Worth, Texas 76102 USA +1 (817) 820-7080 Corporate +1 (817) 820-7076 Direct www.WmgTech.com www.CellerateRX.com www.SecureeHealth.com Deborah Jenkins Hutchinson djenkins@wmgtech.com fidental of Wound Te Inc. 31
Wound Management Technologies — Investor Presentation (October 2010) on 6ix